Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SanBio CoSNBIF 23 EBITDA Margin % is 0.00% as of Jan. 2026. GuruFocus rates SNBIF with a GF Score™ of 23/100. The stock has 1 warning sign investors should review. Among 942 Biotechnology companies, SanBio Co ranks worse than 106157.01% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. SanBio Co's EBITDA for the
three
months ended in Jan. 2026 was $-7.12 Mil. SanBio Co's Revenue for the
three
months ended in Jan. 2026 was $0.00 Mil. Therefore, SanBio Co's EBITDA margin for the quarter that ended in Jan. 2026 was 0.00%.
SanBio Co (OTCPK:SNBIF) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
SanBio Co EBITDA Margin % Related Terms
SanBio Co EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for SanBio Co's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SNBIF vs VRTX, REGN, RVMD: EBITDA Margin % Comparison
For the Biotechnology subindustry, SanBio Co's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SanBio Co EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, SanBio Co's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where SanBio Co's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SanBio Co (SNBIF) has a EBITDA Margin % of 0.00% as of Jan. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on SanBio Co and its competitors. According to the industry distribution chart, SanBio Co ranks #999999 out of 942 companies in the Biotechnology industry.
Is SanBio Co's EBITDA Margin % too high?
SanBio Co's current EBITDA Margin % is 0.00%. Based on the distribution chart, SanBio Co ranks #999999 out of 942 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, SanBio Co has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does SanBio Co's EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, SanBio Co ranks #999999 out of 942 companies for EBITDA Margin %. This places SanBio Co in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on SanBio Co and its competitors. SanBio Co's current EBITDA Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SanBio Co stock overvalued right now?
SanBio Co (SNBIF) has a current EBITDA Margin % of 0.00%. The current EBITDA Margin % is 0.00%. SanBio Co's overall GF Score™ is 23/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For SanBio Co (SNBIF), the current EBITDA Margin % is 0.00% as of Jan. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
SanBio Co Ltd is engaged in the research and development of regenerative cells drugs. The company has three types of drugs under development, including nerve regeneration cell SB623, used for the treatment of chronic cerebral infarction, traumatic brain injury, age-related macular degeneration, retinitis pigmentosa, Parkinson's disease, spinal cord injury and Alzheimer's disease; enhanced type-mesenchymal stem cells SB618, used to treat peripheral neuropathy, as well as muscle stem cells SB308, used in the treatment of muscular dystrophy.
23GF Score
Get the complete analysis for SNBIF
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SNBIF has been successfully added to your 
